ADMA BIOLOGICS, INC.

---

source: coverage-next-full ticker: ADMA step: 01 title: Business Model & Overview created: 2026-06-03

Step 01 — Business Model & Overview: ADMA Biologics, Inc.

Key Findings

Net positive for long-term thesis, conditional on the channel-stuffing allegation being incorrect. ADMA is a vertically integrated specialty biopharmaceutical company with a defensible niche: manufacturing RSV-enriched immune globulin (ASCENIV) for a patient population with no direct competitor. The business model has compelling economics — plasma is collected at ADMA-owned centers, fractionated at its Boca Raton plant, and sold directly to specialty distributors. However, the model's vulnerability is concentration: ~71% of FY2025 revenue came from one product (ASCENIV), and the manufacturing supply chain runs through a single fractionation facility [S1][S3].

Implications for Thesis and Valuation

• ASCENIV's differentiated biology (RSV-enriched plasma pool) creates a premium pricing position not available to commodity IVIG producers. This is the moat worth pricing.
• BIVIGAM is increasingly a drag: it competes with ~5 well-capitalized players (CSL, Grifols, Takeda, Octapharma, Baxter) on price alone [S5]. No pricing power.
• The vertically integrated model (plasma collection → fractionation → commercial) is capital-intensive (10 plasma collection centers, one fractionation plant) but creates a margin flywheel as volumes scale.
• Nabi-HB (hepatitis B IGIV) is a niche product that contributes modestly.

Objective

Map ADMA's business model, value-chain architecture, and revenue layer structure to identify where value is created and where the key risks reside.

Narrative Analysis

ADMA Biologics operates at the intersection of plasma collection, biologics manufacturing, and specialty pharmaceutical commercialization. Unlike most specialty pharma companies that outsource manufacturing, ADMA controls every step of its supply chain — from sourcing plasma at its own collection centers to fractionating and purifying it at its FDA-licensed manufacturing facility in Boca Raton, FL [S1][S3].

The three-product portfolio:

1. ASCENIV (immune globulin intravenous 10%, caprylate chromatography purified): FDA-approved April 2019 for primary humoral immunodeficiency (PI). The key differentiator is ADMA's plasma sourcing protocol, which selects for donors with documented high RSV antibody titers. The resulting product has demonstrably higher RSV neutralizing antibody content than standard IVIG. In the pivotal trial, ASCENIV reduced serious bacterial infections in PI patients and separately demonstrated a reduction in respiratory infection rate from 2.1 to 0.9 per year for PI patients with recurrent lower respiratory infections [S5]. This narrow but validated clinical differentiation drives premium pricing (estimated $90–120K/patient-year vs. $40–60K for standard IVIG). Management guided for ASCENIV at $363M in FY2025 (~71% of total revenue) [S3].

2. BIVIGAM (immune globulin intravenous 10%, caprylate chromatography purified): FDA-approved 2012 for PI. Unlike ASCENIV, BIVIGAM uses a standard plasma pool with no RSV enrichment. It competes head-to-head with Gamunex-C (Grifols), Privigen (CSL Behring), Octagam (Octapharma), and Gammagard (Takeda) — all better-capitalized manufacturers [S5]. BIVIGAM has no pricing power and serves primarily as a base-load utilization vehicle for ADMA's manufacturing plant. Q1 2026 saw BIVIGAM revenue collapse ~54% YoY, suggesting price erosion and/or volume loss is accelerating [S4].

3. Nabi-HB (hepatitis B immune globulin): A legacy product used to prevent HepB recurrence post-liver transplant and after exposure. A small, stable niche product contributing approximately $50–70M annually.

Value chain architecture:

Plasma Donors → ADMA BioCenters (10 centers) → Boca Raton Fractionation Facility
→ ASCENIV / BIVIGAM / Nabi-HB → Specialty Distributors → Specialty Pharmacies → PI Patients

ADMA operates 10 FDA-licensed plasma collection centers under the ADMA BioCenters brand [S3]. These centers collect Source Plasma from paid donors. A critical operational fact: for ASCENIV, ADMA can only use plasma from donors who have documented high RSV antibody titers. This requires either pre-screening (costlier) or a "re-bleed" approach where donors with a history of RSV infection are tracked. This supply constraint caps ASCENIV production volume — it cannot simply scale by buying third-party plasma.

The fractionation facility in Boca Raton is the single-point-of-failure in the supply chain. All products flow through it. This is both a competitive barrier (plasma fractionation requires a FDA BLA and cGMP manufacturing certification that takes 7–12 years to establish) and a concentration risk (a manufacturing shutdown would be catastrophic) [S5].

Evidence and Sources

Revenue and margin data from SEC XBRL and StockAnalysis annual financials [S1][S6]. Product descriptions from 10-K FY2025 business section [S3]. Competitive context from industry research [S5].

Assumption Register Updates

ID	Assumption	Type	Value	Sensitivity	Sources
A-09	ASCENIV pricing ~$90–120K/patient-year vs $40–60K standard IVIG	Estimate	—	High	[S3][S5]
A-10	ADMA has 10 plasma collection centers (BioCenters)	Fact	10	Medium	[S3]
A-11	Boca Raton fractionation plant is the sole manufacturing facility	Fact	1	High	[S3]

Tables and Calculations

Revenue Architecture (FY2025)

Product	Revenue ($M)	% of Total	YoY Growth	Pricing Power
ASCENIV	~363	71%	~51%	HIGH — differentiated biology
BIVIGAM	~95	19%	Declining	NONE — commodity IVIG
Nabi-HB	~52	10%	Stable	LOW — niche, stable
Total	510.2	100%	19.6%

Segment estimates derived from management commentary and 10-K disclosures [S3]

Value-Chain Layer Map

Layer	ADMA Controlled?	Key Assets	Margin Contribution
Plasma Collection	Yes (10 BioCenters)	FDA-licensed centers; RSV-donor network	Cost layer; provides supply control
Plasma Fractionation	Yes	Boca Raton plant (FDA BLA)	High gross margin at scale
Quality Control / Purification	Yes	cGMP certified processes	Embedded in manufacturing
Commercialization	Partial (to distributors)	Sales force; specialty distributor contracts	SG&A; 100% ADMA-owned revenue
Distribution	No	AmerisourceBergen, McKesson, specialty Rx	0% — distributor margin
Patient Services	Indirect	Specialty pharmacy hub	Hub supports access

Open Questions and Data Gaps

1. What is BIVIGAM's trajectory — will ADMA defend it or allow it to wind down?
2. ASCENIV production capacity constraints: how much can output grow given RSV-seropositive plasma supply limits?
3. Is Nabi-HB growing, stable, or declining in unit volume?

Next-Step Dependencies

Step 02 should use the peer universe list in this step and the product-market mapping to assess Porter's five forces for plasma-derived biologics.

Source Index

Source Tag	Document	Section	Date	Notes
[S1]	ADMA_financials/xbrl/xbrl_summary.md	Revenue table	2026-06-03	Annual revenue by year
[S2]	ADMA_financials/sec_filings/filing_inventory.md	Company background	2026-06-03	Filing history
[S3]	ADMA_financials/sec_filings/10K_FY2025_summary.md	Business, MD&A	2026-06-03	10-K FY2025
[S4]	ADMA_financials/other/consensus.md	Q1 2026 miss, BIVIGAM	2026-06-03	Earnings release / Tavily
[S5]	ADMA_financials/industry/competitive_landscape.md	Competitive dynamics	2026-06-03	Industry research
[S6]	ADMA_financials/other/stockanalysis_summary.md	Revenue breakdown	2026-06-03	StockAnalysis.com

---

source: coverage-next-full ticker: ADMA step: 04 title: Financial Quality & Adversarial Sweep created: 2026-06-03

Step 04 — Financial Quality & Adversarial Sweep: ADMA Biologics, Inc.

Key Findings

NET NEGATIVE — material red flags require investigation. The Adversarial Sweep surfaces the Culper Research short report as the dominant concern. The DSO expansion from ~43 days (FY2024) to ~113 days (FY2025) is real, large, and unexplained by management to the market's satisfaction. Multiple securities fraud investigation law firms launched probes [S7]. Q1 2026's $114.5M revenue (vs. $142.7M expected) and guidance cut provided partial validation of the concern [S4]. The financial quality assessment must treat FY2025 revenue as potentially overstated pending investigation, and the analytical base case should use FY2024 as the more reliable baseline.

Setting aside the controversy, underlying financial quality is strong: GAAP-to-cash conversion, low D&A (asset-light fractionation through Q4 2025 CapEx), minimal goodwill, and no evidence of aggressive non-cash accounting [S1][S6].

Implications for Thesis and Valuation

• The FY2025 reported $510M revenue should be treated as a high-confidence floor for the bull case and a questioned number in the bear case (channel stuffing would mean some FY2025 revenue was "borrowed" from FY2026).
• The Q1 2026 AR collection progress ($158M → $136M, a $22M reduction) is a positive data point — distributors are paying down their balances, which is inconsistent with permanent channel stuffing but consistent with a Q4 2025 end-of-year push followed by normal collection.
• If the channel stuffing allegation is false, the stock trades at ~11x trailing P/E on $146.9M net income — a compelling valuation for a profitable, growing specialty pharma.

Objective

Assess the quality of ADMA's reported financials through statement adjustments and an adversarial research sweep covering short-seller reports, investigations, and regulatory concerns.

Narrative Analysis

Statement quality assessment:

Revenue recognition uses ASC 606 (contracts with customers). ADMA sells to specialty distributors under contracts with standard commercial terms. Revenue is recognized when control transfers to the distributor — typically when product ships [S3]. Under this model, revenue can be pulled forward by shipping more product near quarter-end than the distributor would normally order. The key evidence of this:

• FY2025 accounts receivable: $158.4M vs. $50.0M at FY2024 year-end — a $108.4M increase [S1]
• FY2025 revenue growth: $83.7M (+19.6% YoY) [S1]
• The AR increase ($108M) was larger than the revenue increase ($84M), meaning ADMA collected less cash from revenue in FY2025 than in FY2024. This is anomalous.
• DSO calculation: $158.4M / $510.2M × 365 = 113.4 days. For context, the prior year (FY2024) DSO was $50.0M / $426.5M × 365 = 42.8 days — essentially unchanged from FY2023 (~38.7 days). The jump from 43 to 113 is a 2.6x increase in one year [S1].

Management has not provided a satisfactory public explanation (per Tavily research). Possible legitimate explanations: (1) Revised distributor payment terms extended from standard net-30 to net-60 or net-90; (2) A large new distributor relationship with different payment timing; (3) Specialty pharmacy reimbursement timing shifts. None of these have been confirmed [S4].

Adversarial Research Sweep:

Short-seller report — Culper Research (March 26, 2026): Culper alleged that ADMA "channel stuffed" distributors with ASCENIV inventory in Q3 and Q4 2025 to manufacture revenue growth metrics that would sustain management's >$635M FY2026 guidance. Key allegations:

1. DSO jumped from 43 to 113 days — product shipped but not yet paid
2. Management guided for >$635M in FY2026 while internally knowing distributor inventory was elevated
3. CEO and Chairman were selling stock actively in 2025 while guidance was set at unsustainable levels
4. BIVIGAM pricing was under extreme pressure but not communicated transparently The stock fell ~28% in two sessions following the report [S7].

Securities fraud investigations: Following the Q1 2026 earnings miss and guidance cut (May 6, 2026), multiple securities plaintiff law firms (Bernstein Liebhard, etc.) announced investigations into potential securities fraud claims on behalf of ADMA shareholders. These investigations are in their early stages and no formal complaint has been filed, to Tavily's knowledge as of June 2026 [S7].

Regulatory concerns (product quality): No FDA warning letters or consent decrees found for ADMA's Boca Raton manufacturing facility as of 2026 [S2][S3]. ADMA received FDA approval for a yield enhancement process in FY2025, which contributed to the gross margin step-up in Q4 2025 / Q1 2026 (from ~53% to 64–70%). This explains some of the gross margin improvement but does not address the AR build.

Management credibility: CEO Adam Grossman's credibility is at a nadir post-Culper/guidance-cut. However, the Grossman family (Adam + Jerrold) founded the company in 2004 and has significant skin in the game. Jerrold Grossman bought 12,500 shares at $8.01 in May 2026, post-selloff [S8]. If the channel-stuffing allegations were accurate, buying at these prices would be irrational.

Positive financial quality markers:

1. Minimal goodwill ($3.5M) — no acquisition overhang [S6]
2. Low D&A relative to EBITDA — manufacturing is carried at book value, not inflated
3. R&D is minimal ($4.8M FY2025) — company is not burning cash on unproven pipeline [S6]
4. CapEx is modest ($14.4M FY2025) — the fractionation facility is already built [S6]
5. Inventory ($206.5M at FY2025) is high but reflects manufacturing cycle times — plasma to finished product takes 9–12 months [S3]

Assumption Register Updates

ID	Assumption	Type	Value	Sensitivity	Sources
A-18	DSO spike is partially due to pull-forward but Q1 2026 collection suggests normalization	Judgment	—	High	[S1][S4]
A-19	FY2025 revenue may include $50–100M of pull-forward demand; base case uses FY2025 as reported	Estimate	50–100M	High	[S7][S4]
A-20	No FDA warning letters or consent decree found as of June 2026	Fact	N/A	High	[S2][S3]

Tables and Calculations

DSO Analysis

Period	Revenue ($M)	AR ($M)	DSO (Days)	YoY Change
FY2022	154.1	15.5	36.7	—
FY2023	258.2	27.4	38.7	+2 days
FY2024	426.5	50.0	42.8	+4 days
FY2025	510.2	158.4	113.4	+71 days
Q1 2026	114.5 (qtrly)	135.9	~433**	—

Q1 2026 annualized AR/Rev would overstate DSO — on a TTM basis: $135.9M / $509.9M TTM × 365 = ~97 days. AR declining from FY2025's $158.4M is evidence of ongoing collection.

Key Financial Quality Metrics

Metric	FY2024	FY2025	Signal
GAAP Net Income ($M)	197.7	146.9	✓ Real (tax benefit in FY2024)
FCF ($M)	110.5	27.8	⚠️ Large divergence from NI
FCF / Net Income	56%	19%	⚠️ AR build consuming cash
FCF / EBITDA	75%	14%	⚠️ Warning flag
Goodwill ($M)	3.5	3.5	✓ No acquisition distortion
Net Debt ($M)	(19.7)	(7.8)	✓ Near net cash
CapEx / Revenue	2.3%	2.8%	✓ Asset-light for pharma
SBC ($M)	13.6	20.0	Monitor — growing

Adversarial Sweep Summary

Allegation	Evidence For	Evidence Against	Verdict
Channel stuffing (Culper)	DSO 43→113 days; FY2026 guidance cut	AR declining Q1 2026; no confirmed distributor overstock	Unresolved — warrants monitoring
Management credibility	Heavy insider selling FY2025	Founder buyback May 2026	Mixed
Revenue overstatement	Q1 2026 miss vs guidance	New yield enhancement drives GM to 70% — legitimate positive	Unclear magnitude
Regulatory/manufacturing risk	None identified	No FDA warning letters	CLEAR
Securities fraud	Multiple investigations launched	No formal complaint filed	Early stage

Open Questions and Data Gaps

1. What are ADMA's payment terms with specialty distributors? Any changes in FY2025?
2. What is the current distributor inventory level for ASCENIV? Management should address this on Q2 2026 call.
3. Will Q2 2026 AR continue to normalize?

Source Index

Source Tag	Document	Section	Date	Notes
[S1]	ADMA_financials/xbrl/xbrl_summary.md + stockanalysis	Balance sheet, AR	2026-06-03	XBRL + StockAnalysis
[S2]	ADMA_financials/sec_filings/filing_inventory.md	Filing history	2026-06-03	SEC EDGAR
[S3]	ADMA_financials/sec_filings/10K_FY2025_summary.md	Revenue recog, MD&A	2026-06-03	10-K FY2025
[S4]	ADMA_financials/other/consensus.md	Q1 2026, guidance	2026-06-03	Earnings / Tavily
[S6]	ADMA_financials/other/stockanalysis_summary.md	Financial statements	2026-06-03	StockAnalysis
[S7]	ADMA_financials/other/consensus.md; proxy/insider_transactions.md	Culper report, investigations	2026-06-03	Short report + news
[S8]	ADMA_financials/proxy/insider_transactions.md	Insider buys	2026-06-03	Form 4 data

---

source: coverage-next-full ticker: ADMA step: 12 title: Bull vs. Bear — Analyst Debate created: 2026-06-03

Step 12 — Bull vs. Bear: ADMA Biologics, Inc.

Key Findings

High conviction debate. ADMA is a genuine controversy stock in 2026 — the bull and bear cases are not merely different views on growth assumptions but fundamentally different assessments of the integrity of FY2025 revenue. The stock has lost ~57% YTD from $22+ to $7.56 [S7]. Both the bull case (deeply discounted quality company) and the bear case (fraud-adjacent channel-stuffing story with structural BIVIGAM deterioration) are coherent and supported by available evidence. Transcript analysis was not performed — this is the filings-and-consensus path.

The Q1 2026 AR collection data point ($158M→$136M) is the first piece of evidence distinguishing the cases. If channel stuffing were total, distributors would not be paying down balances.

Implications for Thesis and Valuation

• At $7.56, the market is pricing in substantial doubt about FY2025 revenue and/or permanent impairment to the ASCENIV franchise. The question is: what is the normalized earnings power?
• Bull case earnings power: ~$200M EBITDA+ with ASCENIV growth recovery in H2 2026; stock should trade at 10–12x EBITDA = ~$2.0–2.4B EV → ~$8.50–11/share.
• Bear case earnings power: ASCENIV grows modestly but is impaired by channel inventory normalization; BIVIGAM continues to bleed; FY2026E EBITDA ~$130–150M; stock at 8x = ~$1.0–1.2B EV → ~$3–5/share.
• The 3-analyst consensus Buy ratings with average price target ~$26 are clearly stale and have not been reset post-guidance cut [S7]. Ignore them.

Objective

Structure the bull and bear investment debate for ADMA as it stands in June 2026, inferring management and Street views from filings, press releases, and consensus data (no transcripts used).

Narrative Analysis

The debate landscape:

After the Culper report and Q1 2026 miss, ADMA is one of the most controversial small/mid-cap healthcare names in 2026. Three analysts cover the stock, all rated Buy with outdated $26 price targets. The sell-side has not reset to reality. The investor debate is largely driven by the short community (Culper and followers) vs. value investors who see a profitable company at 10–11x trailing P/E.

The crux of the debate: Was the FY2025 revenue growth of 19.6% legitimate, or was it artificially inflated through distributor channel loading?

Bear case arguments (derived from Culper report and market evidence): The $108.4M AR build in FY2025 — more than the full year revenue increase of $83.7M — is the smoking gun. A company cannot grow its accounts receivable faster than revenue in a healthy business environment unless either (a) it extended payment terms, (b) distributors are overloaded, or (c) there is a collection problem. The 46:1 insider sell-to-buy ratio in FY2025 (CEO and Chairman selling aggressively near the high) is circumstantially concerning. BIVIGAM's structural deterioration (-54% YoY in Q1 2026) suggests underlying demand weakness that management may have masked with aggressive ASCENIV booking. The CFO departure in December 2025 — just before the crisis — is a potential governance signal [S8][S9].

Bull case arguments (derived from Q1 2026 data and management filings): The Q1 2026 AR is declining ($158M → $136M) — if channel stuffing were systematic, distributors would not be paying down balances after a revenue miss. The gross margin of 70.5% in Q1 2026 is a company record — this is inconsistent with demand destruction; ASCENIV utilization appears healthy and pricing is holding. The BIVIGAM collapse is structural (commodity IVIG pricing, not ASCENIV), and management clearly differentiated the two products in communications. The founder (Jerrold Grossman) bought shares at $8.01 in May 2026 — small, but genuine skin-in-the-game [S8]. No FDA action, no SEC investigation, no formal litigation filed as of June 2026.

Weighing the evidence: The Q1 2026 gross margin expansion is the most exculpatory data point — if ASCENIV sales were manufactured through channel stuffing, you would expect gross margins to normalize or decline as ASCENIV volumes dropped to reflect real demand. Instead, gross margins hit 70.5% with 71% lower absolute revenue vs. Q4 2025. This suggests that in Q1 2026, ADMA sold fewer total units but those units were predominantly ASCENIV at a high price (or ASCENIV pricing improved). Either way, ASCENIV demand appears real.

The bear case is not refuted — it is merely unresolved. The AR normalization trajectory over Q2–Q4 2026 will be the decisive dataset.

---

Bull Case — 3 Bullets

1. ASCENIV demand is real and growing: Q1 2026's 70.5% gross margin record (despite revenue miss) confirms that the underlying ASCENIV patient franchise is intact and pricing is holding. The Q4 2025 AR build likely reflects year-end specialty pharmacy ordering patterns and extended distributor payment terms, not fraud — and Q1 2026 collection data supports this.

2. Stock is deeply discounted vs. normalized earnings power: At $7.56, ADMA trades at ~10x trailing P/E ($0.60 FY2025 EPS, ~$0.76 annualized Q1 2026 run rate) and ~8.5x EV/EBITDA. For a specialty pharma company with >50% operating margins, 37% ROIC, no direct competitor for its key product, and minimal CapEx requirements, this is a deep-value entry point. The leveraged buyback at $7–10/share creates per-share accretion.

3. FY2026 guidance of $530–560M is achievable and potentially conservative: If ASCENIV continues its patient penetration growth (still only 40–60% of the ~17.5K eligible patients), and BIVIGAM stabilizes at a lower base, FY2026 revenue of $545M+ is credible. FY2026 EBITDA could reach $180–200M at maintained margins, implying ~10–11x EV/EBITDA → $8.50–11/share.

Bear Case — 3 Bullets

1. Channel stuffing was material and FY2025 revenue was overstated: The $108M AR build — 2.6x the prior-year DSO level — points to systematic year-end distributor loading. If $50–100M of FY2025 ASCENIV revenue was "borrowed" from FY2026, the true FY2026 revenue trajectory is impaired and the $530–560M guidance may prove optimistic again. Q2–Q3 2026 will reveal distributor sell-through.

2. Management credibility is permanently impaired, limiting multiple expansion: Even if the fraud allegation proves incorrect, the combination of (a) missing Q1 2026 by 20%, (b) cutting guidance by $90M, (c) a leveraged buyback right before a guidance cut, and (d) heavy insider selling near the high creates a "credibility tax" on the stock. ADMA will likely trade at a discount to specialty pharma peers for 2–4 years while the securities investigations play out and management re-establishes a track record.

3. BIVIGAM structural deterioration is accelerating and may go to near-zero: Standard IVIG pricing is collapsing under competitive pressure from CSL and Grifols, who have better cost structures. BIVIGAM's -54% YoY in Q1 2026 may not be the floor. If BIVIGAM revenue falls from ~$95M (FY2025 estimate) to ~$30–40M, and ASCENIV growth is only modest, FY2026 EBITDA may come in at $130–150M — implying the stock is fairly valued at $7.56.

Open Questions and Data Gaps

1. Q2 2026 AR level — the single most important data point for resolving the debate
2. Product-level revenue disclosure (ASCENIV vs. BIVIGAM vs. Nabi-HB) in Q2 2026 filing
3. SEC subpoena or DOJ inquiry (would escalate bear case significantly)

Source Index

Source Tag	Document	Section	Date	Notes
[S3]	ADMA_financials/sec_filings/10K_FY2025_summary.md	MD&A, products	2026-06-03	10-K
[S4]	ADMA_financials/other/consensus.md	Q1 2026 guidance	2026-06-03	Earnings/Tavily
[S7]	ADMA_financials/other/consensus.md	Culper report	2026-06-03	Short-seller + news
[S8]	ADMA_financials/proxy/insider_transactions.md	Insider data	2026-06-03	Form 4
[S9]	ADMA_financials/proxy/governance_and_compensation.md	Management	2026-06-03	DEF 14A